Molecular evolution of enzymes involved in the arachidonic acid cascade by Toh, Hiroyuki et al.
Invited Review
Mediators of Inflammation 1, 223--233 (1992)
THE metabolic pathway called the arachidonic acid cas-
cade produces a wide range of eicosanoids, such as prosta-
glandins, thromboxanes and leukotrienes with potent bio-
logical activities. Recombinant DNA techniques have
made it possible to determine the nucleotide sequences of
cDNAs and]or genomic structures for the enzymes in-
volved in the pathway. Sequence comparison analyses of
the accumulated sequence data have brought great in-
sights into the structure, function and molecular evolution
of the enzymes. This paper reviews the sequence com-
parison analyses of the enzymes involved in the
arachidonic acid cascade.
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Introduction
Arachidonic acid is released from cell membranes
by chemical, mechanical or electrical stimuli. The
deesterified arachidonic acid is oxygenated to yield a
variety of bioactive compounds---prostaglandins
(POs), thromboxanes (WXs), leukotrienes (LTs),
and lipoxins (LXs). These oxygenated arachidonic
acid compounds are collectively termed ’eicosa-
noids’. Most eicosanoids act as critical mediators in
inflammation, blood clotting, control of vascular
tone, renal function, reproductive systems, and cell
differentiation. In addition, neuronal and neuro-
endocrine functions of eicosanoids have been
discovered recently, and it has been indicated that
eicosanoids play more important roles in inter-
cellular signal transduction systems than those
considered 3reviously. The metabolic pathway
where eicosanoids are formed, is called the
’arachidonic acid cascade’ (see References 1, 2, 3
and 4 for reviews).
One of the prominent achievements in the
research of the arachidonic acid cascade is molecular
cloning of the cDNAs and/or genes for the key
proteins involved in the cascade. 3’4 These proteins
include not only the synthases of eicosanoids, but
also a receptor for an eicosanoid and an activation
factor for a synthase. Sequence comparison
analyses of the sequence data obtained have given
clues to the structures and functions of the proteins.
We focus here on the synthases of eicosanoids, and
discuss the structure, function and molecular
evolution of these enzymes based on the sequence
comparison analyses.
(C) 1992 Rapid Communications of Oxford Ltd
Cyclooxygenase
The arachidonic acid cascade consists of four
metabolic pathways; cyclooxygenase pathway,
lipoxygenase pathway, P-450 pathway and auto-
oxidation pathway. Cyclooxygenase (PG en-
doperoxide synthase, PGG/H synthase) catalyses
the first step in the cyclooxygenase pathway, in
which PGs, TXs and prostacyclin are produced.
Cyclooxygenase is a bifunctional enzyme with
cyclooxygenase activity (arachidonic acid to PGG2)
and peroxidase activity (PGG2 to PGH2),7’8 and
iron(III)-protoporphyrin IX is required for both
activities.7’9’1 The nucleotide sequences of cDNAs
for this enzyme derived from sheep,
1>13 mouse
14
and human
is have been determined. In addition, the
genomic structure for human cyclooxygenase has
been determined.
6 The deduced amino acid
sequences are about 600 residues in length, which
include a signal sequence of about 24 residues. They
are referred to here as cyclooxygenases-1.
Recently, it was found that a mRNA induced by
Rous sarcoma virus in chicken embryo fibroblasts
encodes a protein homologous to cyclooxygenase-
1.17 Furthermore, a mRNA induced by phorbol
ester in Swiss3T3 cells was reported to encode a
cyclooxygenase homologue.
8 The genomic struc-
ture of the latter was recently determined.
9 These
are referred to here as cyclooxygenases-2, although
the details of their functions have not been
established.
The C-terminal region of this enzyme of about
400 residues is homologous to the C-terminal
region of a wide variety of peroxidases--myeloper-
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FIG. 1. (a) Alignment of the peroxidase family around an invariant His
residue. Redrawn from the alignment in Ref. 20. Asterisk indicates
the invariant His residue. ’-’ indicates gap. Open and closed circles under
the alignment indicate invarant sites and sites occupied by physicoche-
mically similar amino acid residues. (1) Sheep cyclooxygenase-1,11 (2)
Human cyclooxygenase-l? (3) Mouse cyclooxygenase-l? (4)
Chicken cyclooxygenase-2,
7 (5) Mouse cyclooxygenase-2,TM (6) Rat
thyroid peroxidase (S07047), (7) Human thyroid peroxidase (A32413),
(8) Pig thyroid peroxidase (A27416), (9) Bovine lactoperoxidase
($16103), (10) Mouse myeloperoxidase,
92 (11) Human myeloperox-
idase,93 and (12) Human eosinophil peroxidase (A34408). The codes in
the parentheses indicate the accession numbers of the proteins in the
N BR F database as references.
(b) Phylogenetic tree of the peroxidase family. Redrawn from the tree
in Ref. 20.
(c) Alignment of EGF-like domains of cyclooxygenases and EGFs.
EGF-like domains of (1) Sheep cyclooxygenase-1,1 (2) Human
cyclooxygenase-1,TM (3) Mouse cyclooxygenase-l? (4) Chicken
cyclooxygenase-2? and (5) Mouse cyclooxygenase-2? and EGFs of
(6) Mouse (EGMSMG), (7) Rat (EGRT), and (8) Human (EGHU). The
codes in the parentheses indicate the accession numbers of the proteins
in the NBRF data base as references. Open circles, closed circles and ’-’
have the same meanings as those in Fig. (a).
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--NPCC---SLP-CQNRGVCMTT-GFDRYECDCTRTGYYGENCTTPEF-FTW-LK
"-NPCC---SNP-CQNRGECMST-GFDQYKCDCTRTGFYGENCTTPEF-LTR-IK
NSYPGCPSSYDGYCLNGGVCMHIESLDSYTCNCV-IGYSGDRCQTRDLRW-WELR
NSNTGCPPSYDGYCLNGGVCMXVESVDRYVCNCV-IGYIGERCQHRDLR
NSDSECPLSHDGYCLHDGVCMYIEALDKYACNCV-VGYIGERCQYRDLKW-WELR
oxidase, eosinophil peroxidase, thyroid peroxidase
and lactoperoxidase. 12’2 In particular, the region
around an invariant His residue (residue position
309 in sheep cyclooxygenase) is remarkably
conserved (Fig. l(a)). 14’2 The invariant His
residue is considered to act as a ligand for heme.
Figure l(b) shows a phylogenetic tree of these
enzymes,
2 which indicates the early divergence of
cyclooxygenases from the other peroxidases. The
cluster made by cyclooxygenases-1 is distinct from
that made by cyclooxygenases-2. Considering that
cyclooxygenases-2 are derived from chicken and
mouse, the divergence between the genes of
cyclooxygenases-1 and -2 occurred before the
species divergence between avians and mammals.
This observation suggests that mammals and avians
have at least two copies of cyclooxygenase-related
genes on their genomes. On the other lineage of
the peroxidase family, thyroid peroxidase function-
ally diverged first. Then, lactoperoxidase diverged.
The divergence between myeloperoxidase and
eosinophil peroxidase occurred last.
2
Both cyclooxygenases-121 and-2
20 contain an
epidermal growth factor (EGF)-like domain down-
stream of the signal sequences (Fig. 1(c)). The
EGF-like domains have been found in a wide
variety of proteins,
22 and are considered to have
been introduced into those proteins by exon
shuffling.
23 The EGF-like domain is encoded by the
third exon in the human cyclooxygenase gene.
6 The
cyclooxygenase has been shown immunohistoche-
mically to be localized at the endoplasmic reticulum
and the nuclear membrane in Swiss 3T3 cells. 24
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Considering that EGF-like domains contain di-
sulphide bridges, the region containing the
EGF-like domain of the cyclooxygenase may at
least be present at the luminal surface. However,
EGF and EGF-like domains are found ordinarily
in extracellular regions, and only the EGF-like
domain of thyroid peroxidase was reported to be
present in the luminal surface of endoplasmic
reticulum.
25 Therefore, the EGF-like domain of this
enzyme is considered to be a second example of the
domain found in cells. However, the functional
meaning of this domain in this enzyme has not yet
been established which is true for most of the
EGF-like domains. Cyclooxygenase contains the
EGF-like domain at its N-terminal region, while
thyroid peroxidase contains the EGF-like domain
at its C-terminal region. Therefore, it is considered
that exon shuffling had occurred independently
twice, in order to introduce EGF-like domains into
the members of the peroxidase family during the
course of evolution.
2
Brain-type PGD Synthase
PGD2 is a maior PG produced in the brain of
humans and rats, and shows a wide variety of
activities in vivo such as sleep induction, hypother-
mia, anticonvulsion, nociception, suppression of
luteinizing hormone release, and modulation of the
odour response.2<27 Brain-type PGD synthase
catalyses the isomerization ofPGH2 to form PGD2.
The nucleotide sequences ofcDNAs for the enzymeMolecular evolution of enwmes involved in the arachidonic acid cascade
from rats
28 and humans
29 were determined. In
addition, the genomic structure for the rat enzyme
was reported.
3 The deduced amino acid sequences
are about 190 residues in length, including a signal
sequence of 20 residues.
This enzyme shows weak (10-33% identity) but
significant sequence homology to the members of
the lipocalin family in their entire regions.29’31 The
lipocalin family consists of a wide variety of small
secretory proteins (160-200 amino acids in length),
which includes fl-lactoglobulin, retinol-binding
protein, bilin-binding protein, 0l-acid glycoprotein,
odorant-binding protein and 02-urinary globu-
lin.32’ These proteins are bound to small lipophilic
molecules and are involved in the transport of those
molecules. The amino acid sequences of the
menbers are different from one another, but six
conserved regions are identified, which characterize
the lipocalins (alignment positions 51, 54-56, 109,
150-152, 181 and 220 in Fig. 2(a)).
32 All these
P.TTFEN-GRCIQRNYSbMBNO-KIKVLNQELP,TVN-Q--
MBBP PBBP
FIG. 2. (a) Alignment of rat brain-type PGD synthase and
seven lipocalins whose genomic structures are known.
Redrawn from the alignment in Ref. 30. Asterisks
indicate stop codons. The positions of the exon/intron
junction are indicated by the numbers on the sequences.
’0’ between two residues indicates splicing between
codons. ’1 ’and "2" on a residue indicate splicing between
the first and second positions of a codon, and that
between the second and third positions of a codon,
respectively. Closed circles, open circles, and ’-" have the
same meanings as those in Fig. (a). (1) Rat brain-type
PGD synthase,3 (2) Mouse 2-urinary globulin,94 (3)
Ovine fl-lactoglogulin,32 (4) Human placental protein 14
(A35570), (5) Human 0l-microglobulin,95 (6) Human
l-acid glycoprotein,96 (7) Rat retinol-binding protein
(VART), and (8) Human apolipoprotein D (A26958). The
codes in the parentheses indicate accession numbers in
the N B R F data base as references.
(b) Model tertiary structure of PGD synthase. Redrawn
from the model in Ref. 29.
(c) Unrooted phylogenetic tree of 26 lipocalins
including brain-type PGD synthases derived from humans
and rats. Re-drawn from the alignment in Ref. 30.
Lipocalins whose tertiary structures are known are boxed.
The abbreviations are as follows: RPDS, rat brain-type
PGD synthase;3 HPDS, human brain-type PGD syn-
thases;29 24p3, mouse 24p3 protein (S07397); C87,
human complement component C87 chain (C8HUG);
2UG, rat 2-urinary globulin;
97 p20K, chicken quiesc-
ene-specific polypeptide 20K (A30230); /LG, ovine
fl-lactoglobulin;32 PP14, human placental protein 14
(A31242); OBP, rat odorant-binding protein (A28713);
APHR, hamster aphrodisin (A31243); PRB, rat probasin
(A32602); PZBP, bovine pyrazine-binding protein
(S06843) 1GP, human -acid glycoprotein (OMHU1);
0dMG, human -microglobulin (HCHU); OBPII, rat
odorant-binding protein II;98 VEGP, rat von Ebner’s gland
protein (S08161); BGP, frog, Rana pipiens, Bowman’s
gland protein (OVFGP); 18.5K, rat androgen-dependent
epididymal 18.5K protein (SQRTAD); RBP, rat retinol-
binding protein (VART); PURN, chicken retinol-binding
protein (A26969); MBBP, tobacco hornworm, Manduca
sexta, bilin-binding protein (CUWlO); PBBP butterfly,
Pieris brasica, bilin-binding protein (S00819); ALPD,
human apolipoprotein D (A26958); CNA2, lobster,
Homarus gammarus, crustcyanin A2.99 CNC1, lobster,
Homarus gammarus, crustcyanin C1. The codes in the
parentheses indicate the accession numbers of the
proteins in the NBRF data base as references.
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conserved regions are also found in the PGD
synthases.
29 In addition to the similarity in sequence
and size, the positions of exon/intron junctions and
the phases of the splicing of this enzyme are similar
to those of the lipocalins (see Fig. 2(a)).
3
The fact that tertiary structures of proteins are
more conserved than their primary structures has
been amply documented.
34-36 In fact, three lipoca-
lins,/g-lactoglobulin,37’38 retinol-binding protein39’4
and bilin-binding protein,41’42 share a common
folding pattern called fl-barrel structure in spite of
the high sequence divergence among them (13-22%
identity). The hydrophobic ligands are bound in the
barrel structure. The sequence homology between
PGD synthases and lipocalins suggests that the
enzyme also has a fl-barrel structure29’31 (Fig. 2(b)).
The enzyme is known to bind to several small
lipophilic molecules including PGH2, the sub-
strate for this enzyme.
29 These molecules may be
bound in the barrel structure as with other
lipocalins.
However, this enzyme has two distinctive
characteristics compared to other lipocalins.29’3
One is that this enzyme has an enzymatic activity,
whereas the other lipocalins are involved in the
transport of small lipophilic molecules. Since the
enzyme requires sulphydryl compounds for the
reaction and is inactivated by treatment with
sulphydryl modifiers, Cys residues are considered to
be involved in the catalytic site of the enzyme. The
sequence comparison between the enzymes from
humans and rats revealed three conserved Cys
residues. Two of them (alignment positions 109 and
220 in Fig. 2(a)) are also conserved in the other
lipocalins, and are involved in the disulphide bridge
formation. The remaining Cys residue is specifically
conserved in the PGD synthase (alignment site 82
in Fig. 2(a)), which may play an important role
in its enzymatic activity. The Cys residue of
alignment site 82 is present in the predicted fl-barrel
structure favourable for interaction with its
substrate (see Fig. 2(b)).
The other distinctive characteristic is that this
enzyme is a membrane associated protein, whereas
the other lipocalins, except for an isoform of
probasin (which reportedly translocates to the
nucleus43), are secretory proteins. It is an important
and interesting problem not only for molecular
evolution but also for protein engineering to
establish the mechanism for the acquisition of the
two characteristics.
Figure 2 (c) shows a phylogenetic tree of the 26
lipocalins including three PGD synthases.
3 The
tree shows that PGD synthase is relatively close to
the p23 oncogene product and the complement
component C8 2 chain, although the similarities of
the enzyme to these two lipocalins are low (23-33%
identity).
PG F Synthase
PGF2 shows activities of bronchoconstriction,
vasoconstriction, luteolysis, and acetylcholine re-
lease. On the other hand, 11-epi-PGF2, the isomer
of PGF2, causes bronchoconstriction, vasocon-
striction, Na+ excretion, urinary excretion, and
antiaggregation. The former is converted from
PGH2 and the latter from PGD2 by the same
enzyme, PGF synthase. Although both activities of
this enzyme require NADPH, the active site for the
PGF2 formation is different from that for
11-epi-PGF2 formation.44’45 The cDNAs encoding
this enzyme were isolated from bovine lung
46 and
liver.47 Both cDNAs encode proteins of 323 amino
acids which are closely related to each other (99%
identity).
PGF synthase shows high sequence similarity to
the members of the aldo-keto reductase family
(36-74% identity).
4 In the presence of NADPH,
PGF synthase catalyses the reduction of not only
PGD2 and PGH2, but also several carbonyl
compounds including 9,10-phenanthrenequinone, a
substrate of the aldo-keto reductases.
48 On
the other hand, human liver aldehyde reductase,
whose sequence shows 40% identity to that of the
PGF synthase, catalyses the reduction of PGH2,
although it does not catalyse the reduction of
PGD2 .49 The aldo-keto reductase family consists of
a wide variety of reductases, such as human liver
chlordechone reductase, Corynebacterium diketoglu-
conic acid reductase, human liver aldehyde
reductase, and aldose reductases from various
mammals. Figure 3(a) is a multiple alignment of
the family including the PGF synthases, and Fig.
3(b) shows an unrooted phylogenetic tree of the
family. As shown in the figure, this enzyme shows
the highest sequence similarity to chlordechone
reductase within the members of the family (74%
identity). It is interesting that frog p-crystallin
occupies a position relatively close to PGF synthase
and chlordechone reductase in the tree. s’sl The
amino acid sequence of frog p-crystallin shows 59%
identity against that of PGF synthase or chlor-
dechone reductase. Recently, it was revealed that
the p-crystallin has an NADPH-binding activity
and shows a weak enzymatic activity to convert
PGH2 to PGF2 (5% of the activity of PGF
synthase), although it does not show the activity to
convert PGD2 to 11-epi-PGF2.
5
There are several crystallins apart from the frog
p-crystallin, which have been identified from
various animals and show high sequence similarity
to the other functionally important enzymes. For
example, g-crystallin from avian and crocodalian
lenses shows high sequence similarity to the lactate
dehydrogenase B4. Furthermore, the &crystallin
shows an enzymatic activity comparable to the
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a FIG. 3. (a) Alignment of aldo-keto reductase family ........................................................................................................................ including PGF synthases. Redrawn from the alignment
QvKL""FEtFTYAsnL-m-"s"’"Q^sEEsc"smm"L in Ref. 51. Open circles, closed circles, and ’-" have
,mumR,R-,-u,,sm,,L,s-sm--m---mm the same meanings as those in Fig. l(a). (1) Bovine
,;,}S -t""stv--[’-*";-mm"""r""u"-*s--""tEt’""""a"m**stmt lung PGF synthase,46 (2) Human chlordecone reductase
*"Es"""---sm"E’*m"""us*n--s-""EE""ms"usm (A34263), (3) Frog, Rana temporaria, p-crystallin,5 (4)
ekskK"cEDEELseAvcLc-ekskHsveevDT"YcvmvL"EDKDLvsKcm"vmmLDLL Corynebacterium diketogluconic acid reductase,TM (5)
PGvAxAA"DAYvYNENvGAENAvLFvKLAFFLvAF"LDLL Leishmania major P100/11 E gene product (A32950), (6)
""vtvx"tatascxvtxta""c"vv""t"tvttxtex’vx"tvsxt’cE"utvxscmsm Yeast nuclear gene GCY product,12 (7) Barley aldose
s-,vt-ms-t,,,c,uv,t,tvtmxt-,x,mvsxt,cs,mtxcxt,m reductase-like protein ($15024), (8) Human aldehyde
LGYDP-PPF-AVADGYHDYYRHEVGAREKVGKREYGKLTDHDPENVPQTLKL .............................. reductase,3 (9) Mouse androgen-dependent protein
HKFvPD-KLFDvDLHEkLCDkGLKSvSHFHKQLLPLKPVCHQvECHP-LQSKLLCSHD-LYk
ETPLPKDE-KFDvDLsAyNEKCAGLASvSCQLEL[PLYKPCQECHP-LQ$KLLDFCSKDv-LkHS
DPDD-PFDDLAELGLLFRRQLELHPLYXPCNQCH-LQLSCSD-LS
TPkD--HkKELkLTSSHLPHLEVkT--PkQELHP-QQETDAkAHDvK-ES
YLDSAEQLYKEIAIGSHFIIIHHLEPYLkNCT--VTPHVHQYELHP-LHHQADLkFCDEQIE-VkS
DTDLTLNHePkRLDPkEDLSvPTKDe^DTNFiETeL-QELTGTKSFSHLDLLSQHKLTPkQP-LLPQDELFCSkS
NPPEkLE-FpNEGYKEAELKDGLKDGYTTLLL-AKPACQNNHGENDFEAC[[HGHTYS
DHPFPKHD-CDSTHEETALALAELQALGLSFSgQDDL$AS--EPAyLQyCP-YLQEEL1A1CQAGLE-Ay-
KDFFPLDEDHP$EDFDTTAELDECLKk$HFHHLQEK1LH[PLPQECHP-YLQKL1QyCK-kYS
KEFFPLDE$-PSDLDNELDEGLkGNFHLENL[PGLYPqECHP-TLTLQYCSKG-TkS
EYFPLDkk-PDDFLDTEALDELVSSFHLELLKKPkNCHP-LKLCHSKG-AS
EFYP-HKSLCLCkL[LSNFRQLEVLKPLKYPTCHP-FTTKLL$SSFAY
(A37990), aldose reductases derived from (10) Bovine
(A35452), (11) Human (S06591), and (12) Rabbit
(A34406), and (13) Rat. A-3-ketosteroid 5fl-reductase
($15835). The codes in the parentheses indicate the
accession numbers of the proteins in the NBRF data base
as references.
(b) Unrooted phylogenetic tree of the aldo-keto
reductase family. The nodes in a circle indicate proteins
which belong to a group designated near the circle.
QGKYDLFGAEPVTAAAAA-HGKTPAQAVLHLQKGFVYFPISVtELEENLDYFDFDLTDTEIAAID
QGK---LLSNPILSAIGAKTNKIAAQVILEVNIQENLITIPESTHEEEIEENADIFDFELGAEDYNSIDALNTNSTGP
TDAP-LLKEPILEIAKENN,QPGHVI$HYQGTVVLPKSTNPDIKTHRE|F--TLSTEDFEAIN
LAHDPVVEVANLNTPGQvLiALQGTSPSSDEKENQVFGPDFKLCSKDvLGELFNHGPiSAADiDHEN-
PLGSS-DAiDPEPLLEEPVLALAKG$PAQLLiQv[VCPSTPSiLQNKYFDFTFSPEENQLNALNKYPL-vDG[DAGHPLPFNDPY
PLPDiPYAPEPVEPEAAHKKTAQLFHQiNvPSTPSiQENLQFDFQLSEDNAALSFNNiACDLLDAT
PLGSP2AKPDP$LEDPRAADKNTTAQvLFPQiNLVPKPEAEFQFDFLDDNTLLSYRDiiACALSCAHi
PLGSPDPiA[PP$LLEDPRKAAAHNTAVLFPQNLPSTPEAENFvFDFLSSQDNTTLLSNiVCALLCTSH
PLGSPDiPiAKPEDPLLDPRKAAKH[TTAQVLFPNQRLPSVPAANFQVFDFELSSDNTTLLSNNiVCALVSCASHK
PLGTCNPLiYNSPPLLDELLTSLKNTQAQvLRFQGLVPSTPEKENFQFDFSLENKDEALNVRFvENLNSDHP
PGF synthase
bovine lung androgen-dependent protein
chlordecone reductase \ mus.,
human [//bovine
p-crystallin \ rabbit aldose reductase
ductase P100/11E gene product -3-ketostero’d 513- e ;e’- "l" PIO
rat Leishmania maior
aldehyde reductase
human / / d ketgolu,CnOencCeird/urme
duc ase
aldose reductase-like protein nuclear gene GCY product
barley yeast
homologous enzyme. Based on these observations,
a new molecular evolutionary mechanism was
proposed. The functional divergence of a gene
product has been considerd to be accompanied by
the duplication of the gene. That is, the relaxation
of the selection pressure to the gene by gene
duplication makes it possible for one copy to
acquire a new function. However, the above
observation suggests another evolutionary mechan-
ism, that is, a gene can acquire new functions
without loss of the original function or gene
duplication. This new mechanism is called ’gene
sharing’,
s2 The sequence homology between PGF
synthase and frog p-crystallin gives an example of
gene sharing.
Recently, the crystal structure of pig aldose
reductase was determined, s3 The enzyme exhibits a
single domain protein with an eight-stranded
parallel o/fl barrel, or a so-called triose phosphate
isomerase (TIM)-barrel structure. The crystallo-
graphic analysis revealed that 2’-monophosphoade-
nosine-5’-diphospho-ribose, which competitively
inhibits the binding of NADPH, binds to a cleft
located at the C-terminal region of the TIM-barrel
Mediators of Inflammation Vol 1992 227H. Toh, Y. Urade and T. Tanabe
structure. This observation suggests that PGF
synthase also has a TIM-barrel structure and
NADPH is bound to the C-terminal region of this
enzyme.
TXA Synthase
TXA2 is a potent inducer of platelet aggregation
and a constrictor of smooth muscles. 54’55 It is known
that this eicosanoid is involved in several diseases
such as thrombosis, atherosclerosis and asthma.
56
TXA synthase catalyses the conversion of PGH2 to
TXA2. TXA synthase and PGI synthase were
purified to homogeneity, and were found to be the
cytochrome P-450 enzymes. 57’s8 Recently, cDNA of
this enzyme was identified from human platelet
59
and lung cDNA libraries,
6 and the complete
sequence of the cDNA was reported. The cDNA
encodes an amino acid sequence of 533 amino acids.
Cytochrome P-450s are ubiquitous in nature and
are found in animals, plants, fungi and bacteria.
P-450s comprise multigene families in living
organisms, and evolutionary relationships among
them have been investigated extensively.
1--3 TXA
synthase (and PGI synthase) is involved in the
cyclooxygenase pathway. Additionally, P-450s are
involved in the cytochrome P-450 pathway to yield
various epoxy-eicosatrienoic acids from arachidonic
acid by their monooxygenase activities.4 On the
other hand, PG c0-hydroxylase was cloned from
rabbit lung,
5 and is involved in c0-oxidation, a step
in metabolic inactivation of PGs. PG co-hydroxylase
also belongs to the cytochrome P-450 family.
Figure 4(a) shows the phylogenetic relationships
between 50 members of the P-450 family including
TXA synthase and PG co-hydroxylase.
6 PG
co-hydroxylase belongs to the P-450 IV family.
Contrary to that, TXA synthase occupies a unique
position in the tree, but it is relatively close to the
P-450 III family, as noted previously.
59 Figure 4(b)
shows the alignment of the TXA synthase and
cytochrome P-450 II1. The Glu (alignment site 406),
Arg (alignment site 409), Phe (alignment site 479),
Cys (alignment site 486) residues are invariant in
the 50 sequences used for construction of the
phylogenetic tree.
The tertiary structure of P-450 CI (or P-450cam)
has been determined.
7 Although the sequence
identity of P-450 CI to other eukaryotic P-450s is
very weak, the other P-450s are considered also to
have a similar folding pattern to that of P-450 CI,
and modellings of the tertiary structures of other
P-450s according to the sequence homology were
tried.
8 The sequence identity between P-450 CI and
TXA synthase is also low, but it is considered that
TXA synthase also has a tertiary structure like that
of P-450 CI.
5- 12- and 15-Lipoxygenases
We have discussed the structure, function and
molecular evolution of the enzymes involved in the
cyclooxygenase pathway. Now we will discuss the
enzymes involved in the lipoxygenase pathway, the
other constituent of the arachidonic acid cascade.
The lipoxygenase pathway is further divided into
three pathways, each of which is initiated by the
oxygenation of arachidonic acid by 5-, 12- and
15-1ipoxygenases, respectively. 3’4 The numbers
attached to the names of the enzymes indicate the
carbon positions of the arachidonic acid, which are
subjected to the oxygenation catalysed by the
corresponding enzymes. The nucleotide sequences
of the cDNAs for the three types of the
lipoxygenases (5-1ipoxygenases derived from hu-
mans9’7 and rats;
71 12-1ipoxygenases derived from
humans72’73 and pigs;74 and 15-1ipoxygenases
derived from humans
7s and rabbits76) have been
determined. Furthermore, the genomic structures
of human 5-1ipoxygenase
77 and rabbit 15-1ipoxy-
genases
78 were determined. The deduced amino
acid sequences are about 700 residues in length, and
the primary structures of 5-, 12- and 15-
lipoxygenases are homologous to each other in
their entire regions. Plants also contain several
lipoxygenases of about 900 amino acid residues in
length. The animal and plant lipoxygenases show
sequence similarity at their C-terminal regions of
about 500 amino acid residues. However, their
N-terminal regions are different not only in amino
acid sequences but also in the lengths.
2
Sequence comparison of animal and plant
lipoxygenases suggests that their primary structures
contain a cluster of invariant His residues (Fig.
5(a)). It is known that lipoxygenases contain a
non-heme iron co-factor, and the invariant His
residues were proposed to act as ligands for the iron
co-factor. 75’79 On the other hand, animal 12- and
15-1ipoxygenases were reported to contain a zinc
finger-like motif, which was also proposed to act as
a ligand for the iron co-factor. However, the motif
is absent in animal 5-1ipoxygenases and plant
lipoxygenases (Fig. 5(b)). 72’74
Figure 5(c) shows a phylogenetic tree of the
lipoxygenases.
2 Two hypothetical ancestral lipoxy-
genases are shown in the tree (lipoxygenase-X and
lipoxygenase-Y). Animal and plant lipoxygenases
diverged at node ’a’. Then, 5-1ipoxygenase and
lipoxygenase-X diverged by gene duplication at
node ’b’. Next, human 12-1ipoxygenase and
lipoxygenase-Y functionally diverged at node’ c’ by
gene duplication of lipoxygenase-X. After that, pig
12-1ipoxygenase and 15-1ipoxygenase diverged at
node ’d’ by gene duplication of lipoxygenase-Y.
Hence, the tree suggests that enzymes with
12-1ipoxygenase activity were created independently
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FH-KS-AISIkEDEEKLESLLSPFISGKLKEEVPIIkQ
FK$DSLFLDEEEGALSAFPEKLEVPL$QACDLLLHLT-GDFDECYCVTDVASVFGTPVDSQAPEDPFHCEFECPPLLLLSFPS
ELAHPEELPPTYL-YLDLLP|EYCKFGSLPEEFLPER$KDDYYPFG
SGRNClGMRALHRHELALIEYLQRFSFIPCETQIPLLSLGGLLQPEEPTVLIESEOGTSGA
kGPRSCLGYRLGLLEIILILLHYLHFRFOACPEIYPLQLESKSXLGPIGII[IS
FIG. 4. (a) Unrooted tree of the cytochrome P-450 family including TXA synthase.
Redrawn from the tree in Ref. 66. The nodes in a circle indicate proteins which
belong to a group designated near the circle. Abbreviations are as follows: txs, human
TXA synthase;59 XXI 1, mouse P-450 XXI (A26660); XXI 2, human P-450 XXl
(04HUC2); IA 3, rabbit P-450 (B27821); IA 4, mouse P-450 (B23923); IA 5,
rainbow trout P-450 (A28789); XVII 6, chicken P-450 XVII (04CHC7); XVII 7, bovine
P-450 XVII (S04346) liD 8, human P-450 lid (S01199); liD 9, rat P-450 liD ($16874)
liD 10, rat P-450 liD (D32970); liE 11, human P-450 liE (B25341); liE 12, rat P-450 liE
(A25341); IIF2, chicken P-450 IIF2 (A31418); IIC 13, rat P-450 IIC (A34258);
IIC 14, rabbit P-450 IIC (A22606); IIC 15, human P-450 IIC (S06306); IIF1, human
P-450 IIF (A36036); liB 16, rat P-450 liB (A29818); IIB17, rabbit P-450 lib
(04RBPB); IIG, rat P-450 IIG (A35551); IIA 18, human P-450 IIA (C34271); IIA 19,
rat P-450 IA (A31887); cv, Streptomyces griseolus P-450 CVA1 (A35401); dnir,
Fusarium oxysporum P-450 dNIR (A40401); pf2, Agrobacterium tumefaciens pinF2
gene product (B32306); CI, Pseudomonas putida P-450 CI (A25660); pfl,
Agrobacterium tumefaciens pinF1 gene product (A32306); XlX 20, chicken P-450 XlX
(A31916); XlX 21, rat P-450 XIX (A36121 ); c7h, human cholesterol 7 hydroxylase;TM
LXXI, Avocado P-450 LXXl (A35867); LI 22, Candida albicans P-450 LI (S02713); LI
23, Saccharomyces cerevisiae P-450 LI (A27491); III 24, rabbit P-450 III (A29487); III
25, human P-450 III (A29815); IV 26, human P-450 IV (A33414); IV 27, rat P-450 IV
(B32965); IV 28, rabbit P-450 IV (C34260); IV 29, rabbit P-450 IV (PG o-hydroxylase)
(A29368); bph, Aspergillus niger benzoate-para-hydroxylase ($12015); CII, Bacillus
megaterium P-450 CII (A34286); LII 30, Candida maltosa P-450 LII (A33254); LII 31,
Candida tropicalis P-450 LII (JS0203) vd, rat 25- hydroxyvitamin D 24- hydroxylase; o5
XXVI, rabbit P-450 XXVI (A33813); XIA 32, bovine P-450 XlA (O4BOM); XIA 33, rat
P-450 XIA (A34164); XIB 34, rat P-450 XlB (A35342); XlB 35, bovine P-450
(A28415). The codes in parentheses indicate the accession numbers of the proteins in
NBRF data base as references.
(b) Alignment between human TXA synthase69 and human P-450 III, whose accession
number in the NBRF database is A29815. Open circles, closed circles and ’-’ have the
same meanings as those in Fig. (a).
twice during the course of molecular evolution. The
tree also suggests that at least two types of plant
lipoxygenases were generated by gene duplication
before the divergence between soybean and garden
pea.
LTA Hydrolase
Leukotriene (LT) A4 is synthesized from
arachidonic acid by the activity of 5-1ipoxygenase,
and all kinds ofLTs are synthesized via LTA4. LTA
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AKCWVRNSDFQLHEIQYHLLNTHLVAEVIAVATMRCLPGLHPIFKFLIPHIRYTMEINTRARTQLISDGGI FD
AKCWVRSSDFQLHELHSHLLRGHLMAEVIAVATMRCLPSIHPIFKLLIPHFRYTMEINVRARNGLVSDLGIFD
AKCWVRSSDFQVHELNSHLLRGHLMAEVFTVATMRCL HPVFKLIVPHLRYTLEINVRAI%NGLVSDFGIFD
AKCWVRSSDFQLHELQSHLLRGHLMAEVIVVATMRCLPSIHPIFKLI PHLRYTLE NVRARTGLVSDMGI FD
AKIWVRSSDFHIHQTITHLLRTHLVSEVFGIAMYRQLPAVHPLFKLLVAHVRFTIAINTKAREQLNCEYGLFD
AKIWVRSSDFHVHQTITHLLRTHLVSEVFGIAMYRQLPAVHPIFKLLVAHVRFTIAINTKAREQLICECGLFD
KAYVIVNDSCYHQLMSHWLNTHAAMEPFVIATHRLSVLH YKLLTPHYRNNMNINALARQ LINANG
AKAYVVVND CYHQLMSHWLNTHAVIEPFIIATNPd4LSALHP YKLLTPHYRDTMNINALARQSLINADGI
AKAYVVVND CYHQLVSHWLNTHAVVE F IATNRHLSVVHP YKLLHPHYRDTMNINGLARLSLVNDC43VIE
AKAYVIVNDSCYHQLVSHWLNTHAVVE FVIATNRHLSCLH YKLLYPHYRDTMNIN LARLSLVNDGG E
b
(I) MCVFTCTAQHAAINQGQLDWYAWVPNAP
(2) MCIFTCTGQHSSNHLGQLDWYTWVPNAP
(3) MCIFTCTGQHSSIHLGQLDWFTWVPNAP
(4) MCIFTCTGQHASVHLGQLDWYSWVPNAP
(5) VVIFTASAQHAAVNFGQYDWCSWlPNAP
(6) VVIFTASAQHAAVNFGQYDWCSWlPNAP
(7) IIIWIASALHAAVNFGQYPYGGLIMNRP
(81 IIIWTASALHAAVNFGQYPYGGFILNRP
(9 IIIWTASALHJkAVNFGQYPYGGLILNRP
[0) IVIWTASAL}LAAVNFGQYSYGGLILNRP
human 12-1ipoxygenase
C
pig 12-1ipoxygenase
rabbit 15-1ipoxygenase
human 15-1ipoxygenase
rat 5-1ipoxygenase
human 5-1ipoxygenase
[
soybean lipoxygenase L-1
[--- soybean lipoxygenase L-2
soybean lipoxygenase L-3
garden pea lipoxygenase
FIG. 5 (a) Alignment of a region including five invariant His residues of ten lipoxygenases. Redrawn from the alignment in Ref. 20. The invariant
His residues are indicated by asterisks on the alignment. (1) Human 12-1ipoxygenase,72 (2) Pig 12-1ipoxygenase,TM (3) Rabbit 15-1ipoxygenase,76 (4)
Human 15-1ipoxygenase,75 (5) Rat 5-1ipoxygenase,71 (6) Human 5-1ipoxygenase,69 (7) Soybean lipoxygenase L-1 (DASYL2), (8) Soybean
lipoxygenase L-2 (DASYL1), (9) Soybean lipoxygenase L-3 (S01864), and (10) Garden pea lipoxygenase (S01142). The codes in the parentheses
indicate the accession numbers of the proteins in the NBRF data base as references.
(b) Alignment of a region including a zinc finger-like motif, Cys-Cys-His-His, of lipoxygenases. Redrawn from the alignment in Ref. 20.
The amino acid residues involved in the proposed motif are indicated by asterisks on the alignment. Open circles, closed circles, and ’-’ have the same
meanings as those in Fig. (a). The numbers (1)-(10) correspond with those in Fig. 5(a).
(c) Phylogenetic tree of lipoxygenase family. Redrawn from the alignment in Ref. 20.
hydrolase is an enzyme which catalyses the
hydrolysis of an epoxide moiety of LTA4 to yield
LTB4. LTB4 is a potent chemotactic compound for
granulocytes and is closely related to the immune
system.
8-82 The nucleotide sequences ofcDNAs for
this enzyme derived from human spleen, lung and
placenta,83’84 and mouse spleen
85 have been
determined, all of which encode proteins 611 amino
acid residues in length. The two human enzymes
are identical to each other and the amino acid
identity between human and mouse enzymes is 93%.
This enzyme shows weak but significant
sequence homology to the members of the
aminopeptidase N family (Fig. 6(a)),86’7 although
the functions of LTA hydrolase is quite different
from that of aminopeptidases. Figure 6(b) shows
the phylogenetic relationships within the amino-
peptidase family including LTA hydrolases.
7 One
of the highly conserved regions between them
corresponds with a ubiquitous sequence motif
found in a wide variety of zinc metalloenzymes.<
The motif sequence, VXXHEXXH (alignment
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sites 349-356), contains two invariant His residues,
which act as ligands for the zinc ion in the proteases.
In addition, it is known that an invariant Glu
residue in the motif is one of the active sites of the
peptidases. These residues are also conserved in the
LTA hydrolase.
After the determination of the sequence homo-
logy, it was revealed by atomic absorption
spectrometry that LTA hydrolase contains one zinc
ion per enzyme molecule.89’9 Furthermore, LTA
hydrolase exhibits peptidase activity toward the
synthetic substrates alanine-4-nitroanilide and
leucine-4-nitroanilide.9’91 The zinc ion was shown
to be involved in both LTA hydrolase activity and
peptidase activity of the enzyme, that is, the
apoenzyme of LTA hydrolase is virtually inactive
for both activities but can be reactivated to show
both activities by the addition of stoichiometric
amounts of zinc or cobalt ion. The LTA hydrolase
undergoes suicide type inactivation, and the
inactivated LTA hydrolase does not show peptidase
activity. The experimental results, in addition to theMolecular evolution of enwmes involved in the arachidonic acid cascade
a
MTQQPQAKYRHDYRAPDYQITDIDLTFDLDAQKqWVT" QAVRHGASDAPL" NDEPWTAWKEEEGAI,
(2) MPEIVDTCSLASPASVCRTKHLHLRCSVD- FTRRTLTGTAALTVQSQEDNLRSLV- -QEVKYALGERQSYKGSPMEISLPIALSKNQEIVI
(3) RVTLRPYLTPNDRGLYVFKGSSTVRFTCKEATDV HSI(KLNYTLSQG-HR-VVLRGVGGSQPPDIDKTELVEPTEYLVVHLKGSLVKDSQYEMDS"
2) KSSALQ-WLTPEQTSGKEHPYL-FSQCQAIHCRAILPCQD-TPS VKLTYTAVSVPKNLVA-LMSAI--RDETPDPEDPSRKI--KFIQKVP’IPCYLIALWGA
(3) -ADDLAGPYRSEYMEGNVRKVVAPQMQAADARKSFPCF’D-EPA MKAEFNITLIHPKDLTA-L-SNMLPKGPSTPLPEDPN’’WNVTEFHTTPKMSTYLL
(I) FDVLRDTFTTRSGREVALELYvDRGNLDRAWAMTSLKNSMKWDRFGLEYDLDIYMIVAVDFFNMAMENKGLNIFNSKYVLARTD
(2) LE’SRQIGP’RTL’’VWSEKEQVEKS--AYEFSETESMLK-’-IAEDLGGPYVWOQYDL LVLPPSFPYGGMENPCL-TFVTPTLLA’OD
(3) FDYVEKQASNGVLIRIWARPSAIAAGHGDYALNVTGPIL-NFFAGHYDTPYPLPKSDQ IGLPD-FNAGAMENWGLVTYRENSLLF--DPLSSSSSNKE’’RVVTVIAHELAHQWFG
(I) NRvTcRDwFQLsLKELTVFRDQEsDLGSRAVNRNNVRTMRLQFAEDAsPMAHRPDMVEMNNFYTLTVYEKGAEVRM1HTLbEENFQKMQYFERHDSA
(2) NLVTNKTWDHFwLNEGHTVYLRHICGRLFGEKFRHFNALGWGELQN.SVKTFGETHFTKLVVDL.TDIDPDVAYSSVYEKGFALLFYLEQLLGGpEIFL-GFKAYVEKFSYKS
(3) NLVTIEWWNDLWLNEGFAsYV.YL.GADYAETWNLKDLMVLNDvYRVMAVDALAssHLsTPAsINTPAQISELFDAIsYSKGASVLRMLSSFLSE.DVFKQG.LASYLHTFAYQNT
(I) ATCDDFVQAMED--ASNVD-LSH FRRwYsQsTITVKDDYNpETEQYTLTISQRTATpDQAK.QLHIFAIELYDNEGKVIPLQKGHPVNsVLNVTQAQTFvFDN
(2) ITTDDwKDFLYsYFKDKVDVLNQV.D.WNAWLYS.GLPIKNYDMTLTNACIAL..SQRWITAKDDLNSFNATDLKDLsSHQLNEFAQTQRApGHIKRMQEVYN.FNAINN
(3) IYLNLWDHLQEAVNNRSIQ.LPTTERDIMNRWTLQ.MFPVITVDTSTGTLsQEHFLLDPDsNVTRPSEFNYA/1qVITSIRDGRQQQDYWLMDV.RAQNDLFST.SGNE.wVLNLN
(l) YFQPVPALLCEFSAPVK- LEYKWSDQQLTFLMR-HARND- FSRWDA-AQSLLATYI -VARHQQG-QPLSLPVHVADAFRAVLLD
(2) "WLRLCIQSKWEDAI -ATEQGRMKFTRPLFKDL- SHDQAV- YQEHKASMHPVTAML’VGKDLK"
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LTA hydrolase
human
LTA hydrolase
mouse
aminopeptidase N
human
aminopeptidase N
rabbit
aminOPrtidase
M
aminopeptidase N
E.coli
FIG. 6 (a) Alignment of aminopeptidase N family including LTA hydrolases. Redrawn from the alignment in
Ref. 87. Open circles, closed circles, and ’-’ have the same meanings as those in Fig. (a). "Z" indicates
the site which is considered to act as a ligand for zinc ion, while indicates the site which is considered to
be an active site for peptidase activity. (1) E. coli aminopeptidase N (DPECN), (2) Human LTA hydrolase,84
and (3) Human aminopeptidase N (S01658). The codes in the parentheses indicate the accession numbers
of the proteins in the NBRF data base as references.
(b) Phylogenetic tree of aminopeptidase N family. Redrawn from the alignment in Ref. 87. The
references or accession numbers for human LTA hydrolase, human aminopeptidase N, and E. coli
aminopeptidase N are the same as those in Fig. 6(a). The accession number for rabbit aminopeptidase N
in the NBRF data base is S07099. The references for mouse LTA hydrolase and rat aminopeptidase M are
Ref. 85 and 86, respectively.
sequence homology, suggest that the catalytic
mechanism of LTA hydrolase is similar to those of
zinc metallopeptidases.
It has been a riddle that LTA hydrolase activity
is found in a wide variety of tissues and cells, some
of which do not express 5-1ipoxygenase activity and,
therefore, are unable to synthesize LTA, the
substrate for this enzyme. The finding of peptidase
activity of this enzyme offers an interpretation that
this enzyme may exert different functions in
different cells and tissues.
91 Further discussion
should be suspended until peptidase activity of this
enzyme is found in vivo. However, it should be
noted that LTA hydrolase is a new type of enzyme
which can utilize two different cellular compounds,
lipids and peptides, as substrates.
Conclusion
We have discussed the structure, function and
molecular evolution of the enzymes involved in
eicosanoid synthesis. Each enzyme discussed here
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has a different origin from another, and sometimes
shows unusual strategies for molecular evolution
(acquisition of enzymatic activity by PGD synthase,
gene sharing by PGF synthase, utilization of two
different types of substrates by LTA hydrolase).
One of our goals is to describe the evolution of
biochemical pathways for eicosanoid metabolism.
However, the sequence data available now are too
scanty for us to make any definite description about
the evolution of the arachidonic acid cascade.
Further, experimental and theoretical approaches
will reveal not only the evolution of the enzymes
involved in the arachidonic acid cascade, but also
the evolution of the cascade itself.
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Note added in proof"
Recently, the crystal structure of myeloperox-
idase was determined (Zengl, Fenna RE. J Mol Biol
1992; 226: 185-207), which may be useful in
investigations of the structure and function of
cyclooxygenase.
Received 1 May 1992"
accepted 20 May 1992
Mediators of Inflammation. Vol 1992 233